­Alkermes’ Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna (paliperidone palmitate) in P-IIIb ALPINE Study to Treat Schizophrenia

 ­Alkermes’ Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna (paliperidone palmitate) in P-IIIb ALPINE Study to Treat Schizophrenia

­Alkermes’ Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna (paliperidone palmitate) in P-IIIb ALPINE Study to Treat Schizophrenia

Shots:

  • The P-IIIb ALPINE Study involves assessing of Aristada and Invega Sustenna in 200 patients experiencing an acute exacerbation of schizophrenia, followed by an outpatient phase for a total of six months
  • P-III study results: @4wks. reductions in Positive and Negative Syndrome Scale (PANSS) total scores (-17.4 points, -20.1 points); @9 & 25 wks. PANSS total scores continued to improve (-19.8 points, -22.5 points & -23.3 points, -21.7 points)
  • Aristada is an injectable antipsychotic available as four doses (441 mg, 662 mg or 882 mg monthly, 882 mg q6w and 1064 mg once every two months) developed for Schizophrenia approved in the US

Click here to read full press release/ article | Ref: Alkermes | Image: American Pharma News

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post